Where next for cell-based therapy in ARDS

Boyle, Andrew James; O'Kane, Cecilia M; McAuley, Daniel F.

doi:10.1136/thoraxjnl-2018-212272

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathophysiology of ARDS is marked by increased inflammation leading to destruction of the alveolar capillary barrier, increased protein leakage and hyaline membrane formation in the alveoli with resultant oncotic pulmonary edema. Ex vivo-generated MSCs have demonstrated biologic efficacy in treating acute lung injury in pre-clinical studies [ 24 , 25 ]. In animal models, bone marrow-derived MSCs were shown to migrate to the lungs where they remained for several weeks without engraftment during which time they released anti-inflammatory paracrine factors such as IL-1 receptor antagonist and prostaglandin E2, improve alveolar fluid clearance, and reduce bacterial overgrowth by releasing anti-microbial peptides [26] , [27] , [28] , [29] , [30] .…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019

et al. 2022

View full text Add to dashboard Cite

“…In recent years, stem cell therapy has become a hot topic worldwide, mainly applied in musculoskeletal diseases, trauma, cornea, cardiovascular diseases and rheumatic system diseases. Mesenchymal stem cell (MSC)-based treatment exerts satisfactory therapeutic effects on ARDS ( Johnson et al, 2017 ; Boyle et al, 2019 ; Yang et al, 2019 ). In preclinical studies, MSCs can be recruited directionally to damaged tissues and exhibit potential therapeutic effects on both infectious and noninfectious lung injury ( Hass et al, 2011 ; Ryan et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Human amnion-derived mesenchymal stem cells attenuate acute lung injury in two different acute lung injury mice models

Sun

Qin

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Acute lung injury (ALI) is one of the most common clinical emergencies with limited effective pharmaceutical treatment in the clinic, especially when it progresses to acute respiratory distress syndrome (ARDS). Currently, mesenchymal stem cells (MSCs) exhibit specific superiority for ALI/ARDS treatment. However, stem cells from different sources may result in controversial effects on similar disease conditions. This study aimed to determine the effects of human amnion-derived mesenchymal stem cells (hAMSCs) on two different ALI mice model. The administered hAMSCs effectively accumulated in the lung tissues in all hAMSC-treated groups. Compared with the model and 1% human serum albumin (HSA) groups, high-dose hAMSCs (1.0 × 106 cells) group significantly alleviated alveolar-capillary permeability, oxidative stress, inflammatory factors level and histopathological damage. In addition, the NF-κB signaling pathway is one of the key pathways activated during lipopolysaccharide (LPS) or paraquat (PQ)-induced lung injury. Our results indicated that hAMSCs (1.0 × 106 cells) obviously inhibited the expression of p-IKKα/β, p-IκBα, and p-p65 in the lung tissue (p < 0.05). The high-dose (HD) hAMSC treatment exerted beneficial therapeutic effects on ALI mice models without detectable adverse reactions. The therapeutic effect of hAMSCs might involve NF-κB signaling pathway inhibition. hAMSC treatment is a potential candidate therapy for ALI.

show abstract

“…The benefit of dexamethasone is believed to be due to its potent immunosuppressive effects. Mesenchymal stromal cells (MSCs) are an emerging novel cellular therapy, which also harness immunomodulatory, reparative, and antimicrobial properties which may be of benefit in targeting the complex pathogenesis of ARDS and sepsis [21]. In this review, we explore the current mechanistic understanding, preclinical, and clinical evidence for MSCs in ARDS and sepsis.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential

Gorman

Millar

O’Kane

2020

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and sepsis due to their reparative, immunomodulatory, and antimicrobial properties. Areas covered: This review provides an overview of Mesenchymal stromal cells (MSCs) and their mechanisms of effect in ARDS and sepsis. The preclinical and clinical evidence to support MSC therapy in ARDS and sepsis is discussed. The potential for MSC therapy in COVID-19 ARDS is discussed with insights from respiratory viral models and early clinical reports of MSC therapy in COVID-19. Strategies to optimize the therapeutic potential of MSCs in ARDS and sepsis are considered including preconditioning, altered gene expression, and alternative cell-free MSC-derived products, such as extracellular vesicles and conditioned medium. Expert opinion: MSC products present considerable therapeutic promise for ARDS and sepsis. Preclinical investigations report significant benefits and early phase clinical studies have not highlighted safety concerns. Optimization of MSC function in preclinical models of ARDS and sepsis has enhanced their beneficial effects. MSC-derived products, as cell-free alternatives, may provide further advantages in this field. These strategies present opportunity for the clinical development of MSCs and MSC-derived products with enhanced therapeutic efficacy.

show abstract

Where next for cell-based therapy in ARDS

Cited by 7 publications

References 29 publications

Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019

Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019

Human amnion-derived mesenchymal stem cells attenuate acute lung injury in two different acute lung injury mice models

Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential

Contact Info

Product

Resources

About